NM23 protein expression in colorectal carcinoma using TMA (tissue microarray): association with metastases and survival

Oliveira, Lauro Augusto de; Neto, Ricardo Artigiani; Waisberg, Daniel Reis; Fernandes, Leandro; Lima, Flávio de Oliveira; Waisberg, Jaques

doi:10.1590/s0004-28032010000400008

Cited by 15 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protein expression of nm23 was assessed in the colorectal carcinoma tissue by immunohistochemistry. This revealed that the protein expression was higher in carcinoma tissue compared with that in adjacent non-neoplastic mucosa, similar to the results of a previous study (14).…”

Section: Discussionsupporting

confidence: 91%

Mutation of the nm23-H1 gene has a non-dominant role in colorectal adenocarcinoma

Jin

Dai

2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Nm23-H1 is a metastasis suppressor gene, which is has a reduced expression in patients with digestive system cancer. However, the mechanistic basis for the genetic instability remains unknown. To study the expression of the nm23-H1 gene in patients with colorectal cancer, polymerase chain reaction-single strand conformation polymorphism was used to analyze any point mutation, and immunohistochemistry was used to detect the expression of nm23-H1. Results revealed that all 63 specimens of Chinese human colorectal cancer tissues exhibit no point mutation. Among those 63 specimens, 19 (30%) exhibited positive immunostaining for the nm23-H1 protein and 44 (70%) exhibited negative immunostaining. These observations suggested that the protein and gene expression levels of nm23-H1 are reduced in colorectal cancer compared with the adjacent normal tissues, and the point mutation in the nm23-H1 gene is not the dominant cause of metastatic colorectal cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Mutation of the nm23-H1 gene has a non-dominant role in colorectal adenocarcinoma

Jin

Dai

2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In CRC many studies managing small series of patients have centred on the tissue expression of NDKA as a prognostic factor for metastasis, with inconclusive results25283031323334.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

Otero-Estévez

Chiara

Barcia-Castro

et al. 2016

Sci Rep

View full text Add to dashboard Cite

We previously described the over-expression of nucleoside diphosphate kinase A (NDKA) in tumours and serum from colorectal cancer (CRC) patients, suggesting its use as biomarker. In this study we evaluated the diagnostic accuracy of serum NDKA to detect advanced neoplasia (CRC or advanced adenomas). Furthermore, the performance of NDKA was compared with the faecal immunochemical test (FIT). The study population included a case-control cohort and a screening cohort (511 asymptomatic first-degree relatives of CRC patients that underwent a colonoscopy and a FIT). Serum NDKA was elevated in CRC patients in the case-control cohort (p = 0.002). In the screening cohort, NDKA levels were higher for advanced adenomas (p = 0.010) and advanced neoplasia (p = 0.006) compared to no neoplasia. Moreover, elevated NDKA was associated with severe characteristics of adenomas (≥3 lesions, size ≥ 1 cm or villous component). Setting specificity to 85%, NDKA showed a sensitivity of 30.19% and 29.82% for advanced adenomas and advanced neoplasia, respectively. NDKA combined with FIT (100 ng/mL cut-off) detected advanced adenomas and advanced neoplasia with 45.28% and 49.12% sensitivity, with specificity close to 90%. The combination of serum NDKA and FIT can improve the detection of advanced neoplasia, mainly for lesions located on the proximal colon, in asymptomatic individuals with CRC family-risk.

show abstract

“…The expression of metastasis suppressor gene nm23 was shown to be higher in neoplastic colorectal carcinoma tissue compared to the adjacent non-neoplastic mucosa, exhibiting a correlation with longer disease-free survival (28). The overexpression of nm23 may be involved in carcinogenesis and a decrease in nm23 expression was previously shown to be associated with metastasis of GI carcinoma (29).…”

Section: Metastasis-associated Genesmentioning

confidence: 92%

Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review)

2013

View full text Add to dashboard Cite

Gastrointestinal (GI) carcinoma is a common malignant disease worldwide. Its development and progression is a multistage process involving a multifactorial etiology. Although the detailed mechanisms of the development of GI carcinoma remain controversial, the elucidation of its molecular biology over the last few years has resulted in a better perspective on its epidemiology, carcinogenesis and pathogenesis. More significantly, it is currently possible to use biological indicators or biomarkers in differential diagnosis, prognostic evaluation and specific clinical interventions. In this review, we aimed to describe the biomarkers of pathogenesis, invasion, metastasis and prognosis of GI carcinoma and discuss their potential clinical applications. The majority of these biomarkers, such as tumor-associated antigens, oncogenes and tumor suppressor genes, metastasis-associated genes, cell adhesion molecules, cytokines, growth factors and microRNAs, are currently broadly applicable.

show abstract

NM23 protein expression in colorectal carcinoma using TMA (tissue microarray): association with metastases and survival

Cited by 15 publications

References 38 publications

Mutation of the nm23-H1 gene has a non-dominant role in colorectal adenocarcinoma

Mutation of the nm23-H1 gene has a non-dominant role in colorectal adenocarcinoma

Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer

Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review)

Contact Info

Product

Resources

About